Drug Profile
LY 3031207
Alternative Names: LY3031207Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Undefined(In volunteers) in USA (PO)
- 09 Oct 2012 Eli Lilly terminates phase I trial in Healthy volunteers in USA (NCT01632566)
- 30 Jun 2012 Eli Lilly initiates enrolment in a multiple-dose Phase-I trial in healthy volunteers in USA (NCT01632566)